Acumen Pharmaceuticals, Inc. (ABOS) annual income statement — 7-year revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.44M | 1.7M |
| Revenue Growth % | - | - | - | - | - | -100% | -15.38% | - |
| Cost of Goods Sold | 46K | 0 | 0 | 0 | 0 | 12.3M | 8M | 8.58M |
| COGS % of Revenue | - | - | - | - | - | - | 556.89% | 505.36% |
| Gross Profit | -46K | 0 | 0 | 0 | 0 | -12.3M | -6.56M | -6.88M |
| Gross Margin % | - | - | - | - | - | - | -456.89% | -405.36% |
| Gross Profit Growth % | - | - | - | - | 100% | -87.55% | 4.62% | - |
| Operating Expenses | 114.56M | 123.83M | 114.02M | 61.14M | 45.24M | 7.28M | 1.35M | 926K |
| OpEx % of Revenue | - | - | - | - | - | - | 94.08% | 54.57% |
| Selling, General & Admin | 18.46M | 18.95M | 20.22M | 18.82M | 12.88M | 7.28M | 1.35M | 926K |
| SG&A % of Revenue | - | - | - | - | - | - | 94.08% | 54.57% |
| Research & Development | 96.1M | 104.89M | 93.8M | 42.32M | 32.36M | 12.3M | 8M | 8.58M |
| R&D % of Revenue | - | - | - | - | - | - | 556.89% | 505.36% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -12.3M | -8M | -8.58M |
| Operating Income | -114.61M | -123.83M | -114.02M | -61.14M | -45.24M | -19.58M | -7.91M | -7.8M |
| Operating Margin % | - | - | - | - | - | - | -550.97% | -459.93% |
| Operating Income Growth % | - | -8.61% | -86.49% | -35.15% | -130.99% | -147.52% | -1.37% | - |
| EBITDA | -114.43M | -123.65M | -113.84M | -60.95M | -45.07M | -19.58M | -7.91M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | -550.97% | - |
| EBITDA Growth % | 9.5% | -8.62% | -86.76% | -35.25% | -130.17% | -147.47% | - | - |
| D&A (Non-Cash Add-back) | 185K | 184K | 178K | 184K | 169K | 4K | 0 | 7.8M |
| EBIT | -110.49M | -117.11M | -98.26M | -51.79M | -42.86M | -19.58M | -7.91M | -7.8M |
| Net Interest Income | 1.77M | 3.22M | 10.25M | 10.21M | 2.39M | 84K | 1K | 45K |
| Interest Income | 6.04M | 7.45M | 14.32M | 10.79M | 2.39M | 84K | 1K | 45K |
| Interest Expense | 4.27M | 4.22M | 4.07M | 581K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 1.33M | 2.5M | 11.69M | 8.77M | 2.38M | -81.02M | 587K | -102K |
| Pretax Income | -113.28M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Pretax Margin % | - | - | - | - | - | - | -510.1% | -465.94% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -113.28M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Net Margin % | - | - | - | - | - | - | -510.1% | -465.94% |
| Net Income Growth % | 2.56% | -18.57% | -95.39% | -22.2% | 57.4% | -1273.46% | 7.36% | - |
| Net Income (Continuing) | -113.28M | -121.33M | -102.33M | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.79 | -2.00 | -1.71 | -1.08 | -1.06 | -2.63 | -0.26 | -0.27 |
| EPS Growth % | 3.61% | -16.96% | -58.33% | -1.89% | 59.7% | -911.54% | 3.7% | - |
| EPS (Basic) | - | -2.00 | -1.71 | -1.08 | -1.06 | -2.63 | -0.26 | -0.20 |
| Diluted Shares Outstanding | 63.22M | 60.56M | 60.01M | 48.61M | 40.6M | 38.27M | 28.65M | 28.65M |
| Basic Shares Outstanding | 63.22M | 60.56M | 60.01M | 48.49M | 40.6M | 38.27M | 28.65M | 28.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ABOS stock.
For fiscal year 2025, Acumen Pharmaceuticals, Inc. (ABOS) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.7M in 2019.
Acumen Pharmaceuticals, Inc. (ABOS) reported a net loss of $121.3M for the fiscal year ending 2025.